Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-TKI + Trastuzumab Rezetecan in Advanced NSCLC with EGFR and HER2 Alterations
NCT07699952Phase 2Not yet recruiting
- Sponsor
- Chengdu Yongsheng Biological Technology
- Start
- Sep 2026
- Primary completion
- Mar 2029
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan in non-small cell lung cancer (NSCLC), sponsored by Chengdu Yongsheng Biological Technology. Primary endpoint: Objective Response Rate at 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07699952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699952.